Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Holzer U et al. – Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of unknown aetiology that affects muscle and skin. The authors report on two patients with severe progressive JDM who developed contractures and were wheelchair dependent despite therapy including methotrexate (MTX), steroids, immunoglobulins, cyclosporin A, and rituximab. ASCT is a therapeutic option with low toxicity for patients with severe, refractory JDM.

Related Articles

Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment
Best Practice & Research: Clinical Rheumatology, 10/28/09    Relevance Score: 67%

Juvenile Dermatomyositis: Advances in Pathogenesis, Evaluation, and Treatment
Pediatric Drugs, 11/09/09    Relevance Score: 65%

Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis
Arthritis & Rheumatism, 11/12/09    Relevance Score: 64%

Rheumatic manifestations of parvovirus B19 in children
Journal of Pediatric Infectious Diseases, 10/15/09    Relevance Score: 64%

Favorable Outcome of Juvenile Dermatomyositis Treated without Systemic Corticosteroids
The Journal of Pediatrics, 10/27/09    Relevance Score: 63%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address